Inducible Nitric Oxide Synthase and L-Arginine Optimizes Nitric Oxide Bioavailability in Ischemic Tissues Under Diabetes Mellitus Type 1.
Journal
Annals of plastic surgery
ISSN: 1536-3708
Titre abrégé: Ann Plast Surg
Pays: United States
ID NLM: 7805336
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
5
12
2019
medline:
15
1
2021
entrez:
5
12
2019
Statut:
ppublish
Résumé
The mechanisms influencing the balance of nitric oxide (NO) bioavailability in tissues are negatively affected under diabetic and also under ischemic conditions. Free tissue transplantation for diabetic patients has to deal with both ischemic and diabetic circumstances, which lead to a significantly decrease in providing NO, thus increasing ischemia-reperfusion injury. In previous studies, we could prove that enhancing NO bioavailability leads to attenuated ischemia-reperfusion injury macrocirculatory and microcirculatory alterations in healthy and also in diabetes type 2 rats. This study is evaluating the role of inducible nitric oxide synthase in different dosages and L-arginine under diabetes type 1 conditions. Diabetic type 1 conditions were established via streptozotocin over a period of 4 weeks and verified via blood sugar, insulin, and C-peptide levels. Vascular pedicle isolated rat skin flap model that underwent 3 hours of ischemia was used. At 30 minutes before ischemia, normal saline, inducible nitric oxide synthase (NOS) (1/2 IE), and L-arginine (50 mg/kg body weight) were administered systemically. Ischemia/reperfusion (I/R)-induced alterations were measured 5 days after the operation. The inducible NOS (iNOS) attenuated I/R-induced alterations under diabetic type 1 conditions significantly with vitality rates of 16.1% compared with control group (5.5%). Best results could be achieved with the combination of iNOS (1 IE) and L-arginine displaying vitality rates of 43%. Increased dosage of inducible nitric oxide (2 IE) led to decreased vitality rates (22.2%/27.4% without/with L-arginine). Supporting the mechanisms of NO bioavailability via exogenous application of iNOS and L-arginine significantly attenuated I/R-induced alterations in a skin flap rat model. This pharmacologic preconditioning could be an easy and effective interventional strategy to uphold conversation of L-arginine to NO even on ischemic and type 1 diabetic conditions.
Sections du résumé
BACKGROUND
The mechanisms influencing the balance of nitric oxide (NO) bioavailability in tissues are negatively affected under diabetic and also under ischemic conditions. Free tissue transplantation for diabetic patients has to deal with both ischemic and diabetic circumstances, which lead to a significantly decrease in providing NO, thus increasing ischemia-reperfusion injury. In previous studies, we could prove that enhancing NO bioavailability leads to attenuated ischemia-reperfusion injury macrocirculatory and microcirculatory alterations in healthy and also in diabetes type 2 rats. This study is evaluating the role of inducible nitric oxide synthase in different dosages and L-arginine under diabetes type 1 conditions.
METHODS
Diabetic type 1 conditions were established via streptozotocin over a period of 4 weeks and verified via blood sugar, insulin, and C-peptide levels. Vascular pedicle isolated rat skin flap model that underwent 3 hours of ischemia was used. At 30 minutes before ischemia, normal saline, inducible nitric oxide synthase (NOS) (1/2 IE), and L-arginine (50 mg/kg body weight) were administered systemically. Ischemia/reperfusion (I/R)-induced alterations were measured 5 days after the operation.
RESULTS
The inducible NOS (iNOS) attenuated I/R-induced alterations under diabetic type 1 conditions significantly with vitality rates of 16.1% compared with control group (5.5%). Best results could be achieved with the combination of iNOS (1 IE) and L-arginine displaying vitality rates of 43%. Increased dosage of inducible nitric oxide (2 IE) led to decreased vitality rates (22.2%/27.4% without/with L-arginine).
CONCLUSIONS
Supporting the mechanisms of NO bioavailability via exogenous application of iNOS and L-arginine significantly attenuated I/R-induced alterations in a skin flap rat model. This pharmacologic preconditioning could be an easy and effective interventional strategy to uphold conversation of L-arginine to NO even on ischemic and type 1 diabetic conditions.
Identifiants
pubmed: 31800556
doi: 10.1097/SAP.0000000000002121
pii: 00000637-202001000-00018
doi:
Substances chimiques
Nitric Oxide
31C4KY9ESH
Arginine
94ZLA3W45F
Nitric Oxide Synthase Type II
EC 1.14.13.39
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-112Références
Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53:503–514.
Pattillo CB, Bir S, Rajaram V, et al. Inorganic nitrite and chronic tissue ischaemia: a novel therapeutic modality for peripheral vascular diseases. Cardiovasc Res. 2011;89:533–541.
Kevil CG, Patel RP. Preserving vessel function during ischemic disease: new possibilities of inorganic nitrite therapy. Expert Rev Cardiovasc Ther. 2008;6:1175–1179.
Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res. 2009;32:1103–1108.
Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, et al. Ischemia/reperfusion injury. J Surg Res. 2002;105:248–258.
Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357:593–615.
Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci (Landmark Ed). 2009;14:1–18.
Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension. 1994;23:1121–1131.
Morris SM Jr., Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol. 1994;266:E829–E839.
Haidara MA, Yassin HZ, Zakula Z, et al. Diabetes and antioxidants: myth or reality? Curr Vasc Pharmacol. 2010;8:661–672.
Sugita H, Kaneki M, Tokunaga E, et al. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab. 2002;282:E386–E394.
Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol. 2006;213–254.
Hansson GK, Geng YJ, Holm J, et al. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med. 1994;180:733–738.
Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 2001;33:1897–1918.
Imamura G, Bertelli AA, Bertelli A, et al. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2002;282:H1996–H2003.
Okazaki T, Otani H, Shimazu T, et al. Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart. J Mol Cell Cardiol. 2011;50:534–544.
Wang WZ, Anderson G, Fleming JT, et al. Lack of nitric oxide contributes to vasospasm during ischemia/reperfusion injury. Plast Reconstr Surg. 1997;99:1099–1108.
Blebea J, Bacik B, Strothman G, et al. Decreased nitric oxide production following extremity ischemia and reperfusion. Am J Surg. 1996;172:158–161; discussion 161-152.
Lejay A, Fang F, John R, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 2016;91:11–22.
Kalogeris T, Baines CP, Krenz M, et al. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229–317.
Abdel-Zaher AO, Abdel-Rahman MM, Hafez MM, et al. Role of nitric oxide and reduced glutathione in the protective effects of aminoguanidine, gadolinium chloride and oleanolic acid against acetaminophen-induced hepatic and renal damage. Toxicology. 2007;234:124–134.
Folli F, Corradi D, Fanti P, et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011;7:313–324.
Erçöçen AR, Apaydin I, Emiroğlu M, et al. The effects of L-arginine and iloprost on the viability of random skin flaps in rats. Scand J Plast Reconstr Surg Hand Surg. 1998;32:19–25.
Schäfer A, Alp NJ, Cai S, et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol. 2004;24:1720–1726.
Wang WZ. Investigation of reperfusion injury and ischemic preconditioning in microsurgery. Microsurgery. 2009;29:72–79.
Khiabani KT, Kerrigan CL. The effects of the nitric oxide donor SIN-1 on ischemia-reperfused cutaneous and myocutaneous flaps. Plast Reconstr Surg. 2002;110:169–176.
Chou CH, Chen LE, Seaber AV, et al. Effect of a nitric oxide donor on microcirculation of acutely denervated skeletal muscle during reperfusion. J Reconstr Microsurg. 2002;18:53–60.
Engel H, Sauerbier M, Germann G, et al. Dose-dependent effects of a nitric oxide donor in a rat flap model. Ann Plast Surg. 2007;58:456–460.
Goyal BR, Solanki N, Goyal RK, et al. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovasc Pharmacol. 2009;54:502–509.
Motyl K, McCabe LR. Streptozotocin, type I diabetes severity and bone. Biol Proced Online. 2009;11:296–315.
Wenzel P, Daiber A, Oelze M, et al. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis. 2008;198:65–76.
Babovic S, Shin MS, Angel MF, et al. Flap tolerance to ischaemia in streptozotocin-induced diabetes mellitus. Br J Plast Surg. 1994;47:15–19.
Cooley BC, Hanel DP, Lan M, et al. The influence of diabetes on free flap transfer: II. The effect of ischemia on flap survival. Ann Plast Surg. 1992;29:65–69.
Dufrane D, van Steenberghe M, Guiot Y, et al. Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation. 2006;81:36–45.
Haidara MA, Mikhailidis DP, Rateb MA, et al. Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications. 2009;23:130–136.
Melin J, Hellberg O, Akyurek LM, et al. Ischemia causes rapidly progressive nephropathy in the diabetic rat. Kidney Int. 1997;52:985–991.
Schmidt RE, Dorsey DA, Beaudet LN, et al. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J Neuropathol Exp Neurol. 2004;63:450–460.
Serdaroglu I, Islamoglu K, Ozgentas E. Effects of insulin-dependent diabetes mellitus on perforator-based flaps in streptozotocin diabetic rats. J Reconstr Microsurg. 2005;21:51–56.
Tatsumi T, Matoba S, Kobara M, et al. Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts. J Am Coll Cardiol. 1998;31:707–715.
Wang WZ, Jones S, Stepheson LL, et al. Microvascular protection induced by late preconditioning was abolished in STZ-induced acute diabetic rats. J Reconstr Microsurg. 2002;18:689–696.
Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017;9:434–449.
Cordeiro PG, Mastorakos DP, Hu QY, et al. The protective effect of L-arginine on ischemia-reperfusion injury in rat skin flaps. Plast Reconstr Surg. 1997;100:1227–1233.
Komorowska-Timek E, Timek TA, Brevetti LS, et al. Oral administration of L-arginine decreases necrosis of the epigastric skin flap in the rat. Ann Plast Surg. 2004;53:73–78.
Chander V, Chopra K. Renal protective effect of molsidomine and L-arginine in ischemia-reperfusion induced injury in rats. J Surg Res. 2005;128:132–139.
Chattopadhyay P, Verma N, Verma A, et al. L-arginine protects from pringle manoeuvere of ischemia-reperfusion induced liver injury. Biol Pharm Bull. 2008;31:890–892.
Anaya-Prado R, Toledo-Pereyra LH, Walsh J, et al. Exogenous nitric oxide donor and related compounds protect against lung inflammatory response after hemorrhagic shock and resuscitation. J Trauma. 2004;57:980–988.
Rusai K, Fekete A, Szebeni B, et al. Effect of inhibition of neuronal nitric oxide synthase and L-arginine supplementation on renal ischaemia-reperfusion injury and the renal nitric oxide system. Clin Exp Pharmacol Physiol. 2008;35:1183–1189.
Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet. 1994;343:1199–1206.
Chiang KT, Shinyashiki M, Switzer CH, et al. Effects of nitric oxide on the copper-responsive transcription factor Ace1 in Saccharomyces cerevisiae: cytotoxic and cytoprotective actions of nitric oxide. Arch Biochem Biophys. 2000;377:296–303.
Koppenol WH, Moreno JJ, Pryor WA, et al. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol. 1992;5:834–842.
Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci. 2001;59:5–16.
Santolini J, Meade AL, Stuehr DJ. Differences in three kinetic parameters underpin the unique catalytic profiles of nitric-oxide synthases I, II, and III. J Biol Chem. 2001;276:48887–48898.
Heusch P, Aker S, Boengler K, et al. Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation. Am J Physiol Heart Circ Physiol. 2010;299:H446–H453.
Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004;44:248–252.
Diodati JG, Quyyumi AA, Keefer LK. Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: hemodynamic effect in the rabbit. J Cardiovasc Pharmacol. 1993;22:287–292.
Gottlieb RA. Cell death pathways in acute ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther. 2011;16:233–238.
Lopez-Neblina F, Toledo AH, Toledo-Pereyra LH. Molecular biology of apoptosis in ischemia and reperfusion. J Invest Surg. 2005;18:335–350.
Oelze M, Schuhmacher S, Daiber A. Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate. Exp Diabetes Res. 2010;2010:213176.